BRIDGEWATER, N.J., Jan. 2, 2024
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global
biopharmaceutical company on a mission to transform the lives of
patients with serious and rare diseases, today announced that
management will present at the 42nd Annual J.P. Morgan
Healthcare Conference in San
Francisco on Monday, January 8,
2024, at 3:00 p.m.
PT/6:00 p.m. ET.
The presentation and question and answer session will be webcast
live and can be accessed by visiting the investor relations section
of the Company's website at www.insmed.com. The webcast
will be archived for a period of 30 days following the conclusion
of the live event.
About Insmed
Insmed Incorporated is a global
biopharmaceutical company on a mission to transform the lives of
patients with serious and rare diseases. Insmed's first commercial
product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung
disease. The Company is progressing a robust pipeline of
investigational therapies targeting areas of serious unmet need,
including neutrophil-mediated inflammatory diseases and rare
pulmonary disorders. Insmed is also advancing an early-stage
research engine encompassing a wide range of technologies and
modalities, including artificial intelligence-driven protein
engineering, gene therapy, and protein manufacturing. Insmed is
headquartered in Bridgewater, New
Jersey, with additional offices and research locations
throughout the United States,
Europe, and Japan. Visit www.insmed.com to learn more.
Contact:
Investors:
Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
bryan.dunn@insmed.com
Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com
Media:
Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-302024202.html
SOURCE Insmed Incorporated